AlphaStocks
4.9
Weak

Biomarin Pharmaceutical Inc (BMRN)

As of Sep 20, 2026, Biomarin Pharmaceutical Inc (BMRN) scores 4.9/10 on AlphaStocks' five-model composite, #118 of 168 Health Care stocks. At $64, BMRN trades 39% above its model fair value of $46.

Health Care / Biotechnology

S&P MidCap 400

$63.94

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#118out of 168 in Health Care

Is BIOMARIN PHARMACEUTICAL INC a Good Investment in 2026?

BIOMARIN PHARMACEUTICAL INC (BMRN) scores 4.9 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating BIOMARIN PHARMACEUTICAL INC as Neutral. However, the Graham model rates it Caution — 69% above fair value. BIOMARIN PHARMACEUTICAL INC currently trades 39% above its estimated fair value of $46. BIOMARIN PHARMACEUTICAL INC ranks #118 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E36.2ROE5.7Market Cap13B

Estimated Fair Value

$45.9439% above

Trading above estimated fair value. P/e of 36x implies high growth expectations. eps growth of -19% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

69% above fair value

Lynch

Neutral

PEG 2.5 · Fast Grower

Greenblatt

Neutral

Earnings yield 3.7% · ROC 10%

Frequently Asked Questions

Is BIOMARIN PHARMACEUTICAL INC (BMRN) a good investment?
As of Sep 20, 2026, Biomarin Pharmaceutical Inc (BMRN) scores 4.9/10 on AlphaStocks' five-model composite, #118 of 168 Health Care stocks. At $64, BMRN trades 39% above its model fair value of $46. That score is below average, suggesting caution.
What is BIOMARIN PHARMACEUTICAL INC's Piotroski F-Score?
BIOMARIN PHARMACEUTICAL INC's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BMRN overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $46, BMRN appears overvalued. The stock currently trades 39% above its estimated fair value. Trading above estimated fair value. P/e of 36x implies high growth expectations. eps growth of -19% may not justify the premium.
How does BMRN compare to other Health Care stocks?
BIOMARIN PHARMACEUTICAL INC ranks #118 out of 168 stocks in the Health Care sector, placing it in the top 70% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about BMRN?
AlphaStocks evaluates BMRN using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 4.9/10.

Similar Stocks

ABBVINCYHRMY

Compare BMRN with

ABBV vs BMRNBMRN vs INCYBMRN vs HRMYBMRN vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer